abstract |
The present invention describes cell-based screening methods that allows for the elimination of false-positive results due to nonspecific toxicity of test compounds, while detecting those compounds that specifically modulate cellular metabolites in metabolic pathways associated with diseases and disorders. The methods of the invention involved determining within a cell system the levels of both a metabolic precursor and a metabolite of interest that are associated with disease and disease progression with particular regard to Alzheimer's disease. |